Monday, June 5, 2023
News on Pathogens and Preparedness
Global Biodefense
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
Global Biodefense
No Result
View All Result
Home Funding News

U.S. Invests $36.3M in Pan-Coronavirus Vaccine Development

by Global Biodefense Staff
September 28, 2021
U.S. Invests $36.3M in Pan-Coronavirus Vaccine Development

Credit: NIAID

The awards are intended to fuel vaccine research for a diverse family of coronaviruses, with a primary focus on potential pandemic-causing coronaviruses, such as SARS-CoV-2.

A critical need remains for prophylactic vaccines offering broad protective immunity against Middle East Respiratory Syndrome Coronavirus (MERS-CoV) and Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV).

The U.S. federal government announced funding this week to multidisciplinary teams to conduct research focused on incorporating understanding of coronavirus virology and immunology, immunogen design, and innovative vaccine and adjuvant platforms and technologies to discover, design, and develop pan-coronavirus vaccine candidates that provide broad protective immunity to multiple coronavirus strains.

The following awards have been issued:

University of Wisconsin, Madison
Project Title: PanCorVac (Center for Pan-Coronavirus Vaccine Development)
Grant: 1 P01AI165077-01

Brigham and Women’s Hospital, Boston
roject Title: Discovering Durable Pan-Coronavirus Immunity
Grant: 1 P01AI165072-01

Duke University, Durham, North Carolina
Project Title: Design and Development of a Pan-Betacoronavirus Vaccine
Grant: 1 P01AI158571-01A1

The awards are will address coronavirus diversity and infectious potential in humans, include innovative immunogen design and vaccine platforms, and approaches to elicit potent and durable pan-coronavirus immunity, and evaluate vaccine candidates in preclinical models.

The awardees are expected to be flexible in the response to emerging knowledge about SARS-CoV-2 immune responses and infection and factor in new information as vaccines candidates are developed.

The new awards total approximately $36.3 million and are funded by the National Institutes of Health’s National Institute of Allergy and Infectious Diseases (NIAID) Division of Microbiology and Infectious Diseases through the Emergency Awards Notice of Special Interest (NOSI) on Pan-Coronavirus Vaccine Development Program Projects. Additional awards are expected from this NOSI, according to NIAID.

READ ALSO:

  • The Search for a Single Vaccine Against Coronaviruses Yet to Come JAMA Network
  • A ‘Universal’ Coronavirus Vaccine to Prevent the Next Pandemic Scientific American
  • Decades-old SARS virus infection triggers potent response to COVID vaccines Nature
Tags: CoronavirusCOVID-19Drug DevelopmentEditor PickNIAIDSARS-CoV-2Vaccines

Related Posts

Vials of finished vaccines
Funding News

UK Biomanufacturing Fund to Bolster Supply Chain Resilience and Pandemic Preparedness

May 26, 2023
Aptitude Awarded Up to $54M BARDA Funding for At-Home Diagnostics
Industry News

Aptitude Awarded Up to $54M BARDA Funding for At-Home Diagnostics

April 20, 2023
Medical Countermeasures

Scientists Design Molecule to Slow SARS-Cov-2 Infection

March 29, 2023
Partner Therapeutics’ Novel Approach to Stratify Sepsis Patients Gains Backing From BARDA
Funding News

Biopreparedness Research Virtual Environment (BRaVE) Initiative Backed by $105M DOE Funding

January 25, 2023
Load More

Latest News

Vials of finished vaccines

UK Biomanufacturing Fund to Bolster Supply Chain Resilience and Pandemic Preparedness

May 26, 2023
Dr. Sen Pei Discusses Challenges in Forecasting Antimicrobial Resistance

Dr. Sen Pei Discusses Challenges in Forecasting Antimicrobial Resistance

April 26, 2023
Biodefense Headlines – 25 April 2023

Biodefense Headlines – 25 April 2023

April 25, 2023
Aptitude Awarded Up to $54M BARDA Funding for At-Home Diagnostics

Aptitude Awarded Up to $54M BARDA Funding for At-Home Diagnostics

April 20, 2023

Subscribe

  • About
  • Contact
  • Privacy
  • Subscribe

© 2023 Stemar Media Group LLC

No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe

© 2023 Stemar Media Group LLC

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are okay with it.OkPrivacy policy